FDA grants full approval to first drug for rare kidney disease

Food and Drug Administration (FDA) reached a historic milestone by granting full approval to Filspari (sparsentan).

This medication is the first-ever treatment specifically approved for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease.

FSGS causes scarring in the kidney’s filtering units, often leading to total organ failure.

For years, patients relied on off-label treatments like steroids, which frequently came with severe side effects.

Filspari, an oral, once-daily drug, works by targeting the inflammatory pathways that cause scarring and protein leakage.

While it carries a warning for liver toxicity, its approval offers new hope to over 30,000 patients in the United States who previously lacked a dedicated therapy.

By focusing on proteinuria reduction, Filspari aligns with modern clinical guidelines, marking a major success in the medical community’s effort to slow the progression of chronic kidney conditions and improve long-term outcomes for those living with this challenging disease.